Improving risk‐stratification of natalizumab‐associated PML

Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)

(2020) Helmut Butzkueven et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing

(2019) John F. Foley et al.   Multiple Sclerosis and Related Disorders

The risk of PML from natalizumab – Authors' reply

(2019) Pei-Ran Ho et al.   LANCET NEUROLOGY

Should frequent MRI monitoring be performed in natalizumab-treated MS patients? A contribution to a recent debate

(2019) Cristina Scarpazza et al.   Multiple Sclerosis Journal

Natalizumab-associated progressive multifocal leukoencephalopathy in Germany

(2019) Kira Blankenbach et al.   NEUROLOGY

Treatment of natalizumab‐associated PML with filgrastim

(2019) Dusan Stefoski et al.   Annals of Clinical and Translational Neurology

Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals

(2019) Nicholas Schwab et al.   NEUROLOGY

Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France

(2019) Sandra Vukusic et al.   JAMA Neurology

The 5-year Tysabri Global Observational Program in Safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis

(2019) John Foley et al.   Multiple Sclerosis and Related Disorders

Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned

(2018) Eugene O Major et al.   LANCET NEUROLOGY

Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution

(2018) Cristina Scarpazza et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Impact of Disease-Modifying Treatments on the Longitudinal Evolution of Anti-JCV Antibody Index in Multiple Sclerosis

(2018) Harald Hegen et al.   Frontiers in Immunology

Natalizumab therapy is associated with changes in serum JC virus antibody indices over time

(2017) John Peters et al.   JOURNAL OF NEUROLOGY

Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies

(2017) Pei-Ran Ho et al.   LANCET NEUROLOGY

Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters

(2017) Nicholas Schwab et al.   Multiple Sclerosis Journal

PML in natalizumab-treated multiple sclerosis

(2017) Ellen M. Mowry et al.   NEUROLOGY

Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters

(2017) Nicholas Schwab et al.   Multiple Sclerosis Journal

Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy

(2015) Anke Vennegoor et al.   Multiple Sclerosis Journal

Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy

(2015) Anke Vennegoor et al.   Multiple Sclerosis Journal

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy

(2014) Tatiana Plavina et al.   ANNALS OF NEUROLOGY

MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study

(2014) R. J. Fox et al.   NEUROLOGY

Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study

(2014) P. O'Connor et al.   NEUROLOGY

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients

(2014) Tuan Dong-Si et al.   Annals of Clinical and Translational Neurology

PML diagnostic criteria: Consensus statement from the AAN Neuroinfectious Disease Section

(2013) J. R. Berger et al.   NEUROLOGY

Classification of Natalizumab Cases with Progressive Multifocal Leukoencephalopathy (P07.058)

(2012) T. Dong-Si et al.   NEUROLOGY

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY-1

(2011) Carmen Bozic et al.   ANNALS OF NEUROLOGY